Literature DB >> 15623353

An action spectrum of the riboflavin-photosensitized inactivation of Lambda phage.

Christopher B Martin1, Erin Wilfong, Patrick Ruane, Raymond Goodrich, Matthew Platz.   

Abstract

The Action Spectrum of riboflavin (RB) sensitized inactivation of lambda phage was determined between 266 and 575 nm. Below 304 nm, RB depresses the phage reduction by screening phage from radiation that it would otherwise absorb directly. Between 308 and 525 nm, RB sensitizes the inactivation of phage. Enhanced phage reduction is observed at 320 and 500 nm because of binding of RB to the phage and the shifting of the absorption curve of the phage-bound flavin relative to free flavin in phosphate-buffered saline. Enhanced inactivation at 320 and 500 nm and depressed phage inactivation between 360 and 410 nm is also influenced by the inner filter effect.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15623353     DOI: 10.1562/2004-08-25-RA-292

Source DB:  PubMed          Journal:  Photochem Photobiol        ISSN: 0031-8655            Impact factor:   3.421


  7 in total

1.  Response to: Evaluation of combined riboflavin and ultraviolet A as an alternative treatment for keratitis.

Authors:  Karim Makdoumi; Jes Mortensen; Sven Crafoord
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-02-17       Impact factor: 3.117

2.  Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light.

Authors:  Susanne Marschner; Raymond Goodrich
Journal:  Transfus Med Hemother       Date:  2011-01-31       Impact factor: 3.747

3.  Understanding loss of donor white blood cell immunogenicity after pathogen reduction: mechanisms of action in ultraviolet illumination and riboflavin treatment.

Authors:  Rachael P Jackman; John W Heitman; Susanne Marschner; Raymond P Goodrich; Philip J Norris
Journal:  Transfusion       Date:  2009-08-04       Impact factor: 3.157

4.  A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge Model.

Authors:  Izabela K Ragan; Lindsay M Hartson; Taru S Dutt; Andres Obregon-Henao; Rachel M Maison; Paul Gordy; Amy Fox; Burton R Karger; Shaun T Cross; Marylee L Kapuscinski; Sarah K Cooper; Brendan K Podell; Mark D Stenglein; Richard A Bowen; Marcela Henao-Tamayo; Raymond P Goodrich
Journal:  Vaccines (Basel)       Date:  2021-04-01

5.  The Mirasol Evaluation of Reduction in Infections Trial (MERIT): study protocol for a randomized controlled clinical trial.

Authors:  Ronnie Kasirye; Heather A Hume; Evan M Bloch; Irene Lubega; Dorothy Kyeyune; Ruchee Shrestha; Henry Ddungu; Hellen Wambongo Musana; Aggrey Dhabangi; Joseph Ouma; Priscilla Eroju; Telsa de Lange; Michael Tartakovsky; Jodie L White; Ceasar Kakura; Mary Glenn Fowler; Philippa Musoke; Monica Nolan; M Kate Grabowski; Lawrence H Moulton; Susan L Stramer; Denise Whitby; Peter A Zimmerman; Deo Wabwire; Isaac Kajja; Jeffrey McCullough; Raymond Goodrich; Thomas C Quinn; Robert Cortes; Paul M Ness; Aaron A R Tobian
Journal:  Trials       Date:  2022-04-04       Impact factor: 2.279

6.  A minimally manipulated preservation and virus inactivation method for amnion/chorion.

Authors:  Shang Zhang; Lichang Gao; Pin Wang; Yuyan Ma; Xiaoliang Wang; Jie Wen; Yu Cheng; Changlin Liu; Chunxia Zhang; Changfeng Liu; Yongli Yan; Chengru Zhao
Journal:  Front Bioeng Biotechnol       Date:  2022-08-11

Review 7.  Photodynamic inactivation of mammalian viruses and bacteriophages.

Authors:  Liliana Costa; Maria Amparo F Faustino; Maria Graça P M S Neves; Angela Cunha; Adelaide Almeida
Journal:  Viruses       Date:  2012-06-26       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.